Health
Sanofi discontinues cancer research programme to evaluate tusamitamab ravtansine
French healthcare company Sanofi on Thursday said it was ending a programme to evaluate tusamitamab ravtansine linked to the treatment of various types of lung
US FDA approves first test to detect risk of addiction to opioids
The US Food and Drug Administration said it has approved the first test to assess whether certain people are at risk of addiction to opioids.
US FDA approves first test to detect risk of addiction to opioids
The US Food and Drug Administration said it has approved the first test to assess whether certain people are at risk of addiction to opioids.
Doctors-in-training in England step up strikes
Doctors in training in England have stepped up their industrial action, initiating the first walkout of their biggest strike to date. Hospitals warn that this
WHO states that the JN.1 COVID strain is a “variant of interest” and poses a low risk
The World Health Organisation has classified the JN.1 coronavirus strain as a “variant of interest” and said current data show that the public health risk
Novo owner to direct $265m Wegovy to respiratory diseases
The Novo Nordisk Foundation announced that the government will provide up to $265 million for an initiative to improve vaccines against respiratory diseases. Novo Nordisk’s
Planned Parenthood rejected a ban on abortion in Kentucky
Lawyers for Planned Parenthood and other groups said Monday they dropped a class action lawsuit challenging Kentucky’s near-total abortion ban after the named plaintiff lost
BioNTech plans to start mRNA vaccine production in Rwanda in 2025
COVID-19 vaccine maker BioNTech plans to start production of its mRNA vaccine plant in Rwanda in 2025, company officials said on Monday, the first mRNA
Novo to spend 265 million of Wegovy’s revenues on respiratory diseases
The Novo Nordisk Foundation, which controls drug maker Novo Nordisk, said Monday the government will allocate up to 1.8 billion Danish kroner ($265 million) for
GSK’s anticancer drug combination has achieved a major late-stage study target
GSK said on Monday its cancer drug Jumperly alongside chemotherapy, followed by Zejula and Jumperly as maintenance therapy achieved its primary goal of progression-free survival